Jazz Pharmaceuticals’ (JAZZ) “Buy” Rating Reiterated at Needham & Company LLC

Needham & Company LLC reiterated their buy rating on shares of Jazz Pharmaceuticals (NASDAQ:JAZZ – Free Report) in a research note released on Thursday morning,Benzinga reports. They currently have a $210.00 price target on the specialty pharmaceutical company’s stock. A number of other equities research analysts have also recently weighed in on JAZZ. Cantor Fitzgerald […]